WebNov 8, 2024 · Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and ... WebFeb 6, 2024 · Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling results involving OBD’s technology in the multi-disciplinary PROSTAGRAM study using blood to detect prostate cancer in an at risk …
Oxford BioDynamics Awarded US FNIH Grant to Apply EpiSwitch
Web1 day ago · Oxford BioDynamics plc (OBD) is a United Kingdom-based biotechnology company. The Company is advancing personalized healthcare by developing and commercializing precision medicine tests for diseases, based on the Company’s three-dimensional (3D) genomics platform, EpiSwitch. WebMar 29, 2024 · Oxford BioDynamics (LON:OBD) has a recorded net income of -£6.71 million. OBD has generated -GBX 0.06 earnings per share over the last four quarters. More Earnings Resources from MarketBeat how to spell christiansen
Oxford BioDynamics Stock Forecast: down to 0.6044 USD ...
WebNov 21, 2024 · OBD is the commercial pioneer and technological leader in isolating and analyzing 3D genomic biomarkers from a simple blood draw to guide treatment decisions, assess prognosis, and predict therapy... WebNov 2, 2024 · Dr. Jon Burrows, CEO of Oxford BioDynamics commented: “Working with an established integrated industry partner is another step on the path to commercializing our disease severity program for ... WebOBD’s proprietary EpiSwitch technology maps this 3D architecture at scale, identifying abnormal configurations that can be used to diagnose patients or predict how someone … rdl instructions